Biosimilars
Antibody Biosimilars
Celltrion develops antibody biosimilars that are as effective as the higher-priced original biopharmaceuticals. Biosimilars have no clinical differences in terms of quality, efficacy and safety from original biologics. This enables more people to benefit from quality medical care at reasonable costs and alleviates financial burden on public healthcare. With the launch of the world’s first mAb biosimilar, Remsima, we have successfully developed and commercialized various biosimilar products.Celltrion's REMSIMA
Reference drugBiosimilar ABiosimilar BAnticancer drug
Breast cancer, colorectal cancer, kidney cancer, cervical cancer, Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, etc.Immune disease treatment
Rheumatoid arthritis, psoriasis, ankylosing spondylitis, inflammatory bowel disease etc.Other targeted therapy
Osteoporosis, asthma, macular degeneration
